Oncocyte Corporation (NASDAQ:OCX) has a beta value of 0.86 and has seen 73907.0 shares traded in the last trading session. The company, currently valued at $53.91M, closed the last trade at $2.56 per share which meant it gained $0.18 on the day or 7.56% during that session. The OCX stock price is -35.94% off its 52-week high price of $3.48 and 25.0% above the 52-week low of $1.92. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.1 million shares traded. The 3-month trading volume is 98.72K shares.
The consensus among analysts is that Oncocyte Corporation (OCX) is Buy stock at the moment, with a recommendation rating of 2.33. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 1 out of 4 have rated it as a Hold, with 3 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is 0.
Oncocyte Corporation (NASDAQ:OCX) trade information
Sporting 7.56% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the OCX stock price touched $2.56 or saw a rise of 1.54%. Year-to-date, Oncocyte Corporation shares have moved 7.56%, while the 5-day performance has seen it change 27.36%. Over the past 30 days, the shares of Oncocyte Corporation (NASDAQ:OCX) have changed 16.36%. Short interest in the company has seen 0.34 million shares shorted with days to cover at 6.83.
Wall Street analysts have a consensus price target for the stock at $10, which means that the shares’ value could jump 74.4% from current levels. The projected low price target is $4.25 while the price target rests at a high of $10.0. In that case, then, we find that the current price level is -290.62% off the targeted high while a plunge would see the stock gain -66.02% from current levels.
Oncocyte Corporation (OCX) estimates and forecasts
The company’s shares have lost -16.07% over the past 6 months. Revenue growth from the last financial year stood is estimated to be -66.73%.
3 analysts offering their estimates for the company have set an average revenue estimate of 101.67k for the current quarter. 2 have an estimated revenue figure of 158.55k for the next ending quarter. Year-ago sales stood 314k and 176k respectively for this quarter and the next, and analysts expect sales will shrink by -67.62% for the current quarter and -66.73% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 14.72% over the past 5 years. Earnings growth for 2025 is a modest 26.93% while over the next 5 years, the company’s earnings are expected to increase by 28.77%.
OCX Dividends
Oncocyte Corporation is expected to release its next earnings report in March this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Oncocyte Corporation (NASDAQ:OCX)’s Major holders
Insiders own 16.32% of the company shares, while shares held by institutions stand at 66.60% with a share float percentage of 79.59%. Investors are also buoyed by the number of investors in a company, with Oncocyte Corporation having a total of 29.0 institutions that hold shares in the company. The top two institutional holders are AWM INVESTMENT COMPANY, INC. with over 1.1 million shares worth more than $3.24 million. As of 2024-06-30, AWM INVESTMENT COMPANY, INC. held 13.2766% of shares outstanding.
The other major institutional holder is DEFENDER CAPITAL, LLC., with the holding of over 55220.0 shares as of 2024-06-30. The firm’s total holdings are worth over $0.16 million and represent 0.6682% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. As of Sep 30, 2024 , the former fund manager holds about 0.89% shares in the company for having 154.88 shares of worth $0.4 million while later fund manager owns 85.0 shares of worth $0.22 million as of Sep 30, 2024 , which makes it owner of about 0.49% of company’s outstanding stock.
